Philadelphia, PANCT05674175Now EnrollingIRB Ready

B-cell Acute Lymphoblastic Leukemia Clinical Trial in Philadelphia, PA

Access cutting-edge b-cell acute lymphoblastic leukemia treatment through this phase 1/2 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Stephan Grupp MD PhD

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access b-cell acute lymphoblastic leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related b-cell acute lymphoblastic leukemia treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this b-cell acute lymphoblastic leukemia clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This B-cell Acute Lymphoblastic Leukemia Study in Philadelphia

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

Sponsor: Stephan Grupp MD PhD

Who Can Participate

Inclusion Criteria

Signed informed consent form
Patients with documented CD19+ and/or CD22+ ALL/LLy:
Cohort A: Patients with relapsed or refractory ALL/LLy:
Cohort B: Patients with poor response to prior B cell directed engineered cell therapy
Patients with prior or current history of Central Nervous System 3 disease will be eligible if Central Nervous System disease is responsive to therapy
Documentation of CD19 and/or CD22 tumor expression in bone marrow, peripheral blood, Cerebrospinal fluid, or tumor tissue by flow cytometry at the time of last detectable disease. If the patient has experienced a relapse after CD19-directed and/or CD22-directed therapy, flow cytometry should be evaluated after this therapy to demonstrate CD19 and/or CD22 expression.
Age 0-29 years
Adequate organ function
Adequate performance status defined as Lanksy or Karnofsky performance score ≥50.
Subjects of reproductive potential must agree to use acceptable birth control methods.

Exclusion Criteria

Active hepatitis B or active hepatitis C
HIV infection
Active acute or chronic Graft Vs. Host Disease requiring systemic therapy
Concurrent use of systemic steroids or immunosuppression at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy or immunosuppression during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well.
Central nervous system disease that is progressive on therapy, or with Central nervous system parenchymal lesions that might increase the risk of central nervous system toxicity.
Pregnant or nursing (lactating) women
Uncontrolled active infection

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT05674175) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

B-cell Acute Lymphoblastic Leukemia Treatment Options in Philadelphia, PA

If you're searching for b-cell acute lymphoblastic leukemia treatment options in Philadelphia, PA, this clinical trial (NCT05674175) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced b-cell acute lymphoblastic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all b-cell acute lymphoblastic leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Philadelphia, PA

See all leukemia clinical trials recruiting in Philadelphia — not just this study.

Browse Leukemia Trials in Philadelphia →

Browse More Trials by Condition

Leukemia TrialsB-Cell Acute Lymphoblastic Leukemia TrialsHeart Attack TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA